My first aim identified enrollment patterns and variables that predict enrollment in a diverse
underserved population and evaluated barriers to enrollment. We analyzed data from the …

Objective Taxane containing chemotherapy extends survival for breast cancer patients.
However, taxane-induced peripheral neuropathy (TIPN) cannot be predicted, prevented or …

Background Paclitaxel-induced neuropathy is an adverse event that often leads to
therapeutic disruption and patient discomfort. We attempted to replicate a previously …

The development of paclitaxel-induced peripheral neuropathy (PIPN) is influenced by drug
exposure and patient genetics. The purpose of this analysis was to expand on a previous …

12089 Background: Taxane-induced peripheral neuropathy (TIPN) is a common dose-
limiting toxicity in the medical management of breast cancer patients. Despite the clinical …

Purpose: Paclitaxel is a widely used anticancer therapeutic. Peripheral neuropathy is the
dose-limiting toxicity and negatively impacts quality of life. Rare germline gene markers …

10515 Background: Peripheral neuropathy is the most common severe toxicity in patients
treated with paclitaxel. Putative genetic mutations in genes relevant to drug metabolism …

LBA503 Background: Black women experience higher rates of TIPN compared to White
women when receiving weekly paclitaxel (WP) for early-stage breast cancer. This disparity …

Purpose: Paclitaxel, a widely used chemotherapeutic drug, can cause peripheral
neuropathies leading to dose reductions and treatment suspensions and decreasing the …

PURPOSE Black women experience higher rates of taxane-induced peripheral neuropathy
(TIPN) compared with White women when receiving adjuvant once weekly paclitaxel for …